INTRODUCTION

Despite the development of several multidisciplinary diagnosis/therapies, including surgery, radiotherapy, chemotherapy, and molecular approaches, esophageal cancer continues to remain as one of the worst malignant neoplasms of the digestive system. Recently, immune checkpoint inhibitors for advanced esophageal cancer...
were introduced as a new therapeutic agent. Among them, the expression of tissue programmed death ligand 1 (PD-L1) was assessed; however, an assessment of serum PD-L1 levels to evaluate the clinicopathological characteristics of the patients with esophageal cancer has not been made so far.

Recently, several reports have shown that high serum PD-L1 level is a prognostic factor for poor overall survival in patients with gastric cancer, hepatocellular carcinoma, and biliary tract cancer. Akutsu et al reported the clinicopathological significance of serum PD-L1 levels in esophageal cancer patients. However, their report included only 26 surgically treated cases, other cases were 20 endoscopic submucosal dissection treated cases, and 39 nonsurgical treated cases. Furthermore, Weber et al reported that serum PD-L1 mRNA expression was a prognostic marker in patients with oral squamous cell carcinoma. However, they did not evaluate the relationship with other tumor markers, laboratory data, and pathological factors in resected specimens.

Tumor PD-L1 expression and/or serum PD-L1 levels have been associated with inflammatory biomarkers, such as high white blood cell count, CRP levels, and IL-6 expression in various types of tumors. To the best of our knowledge, correlations between serum PD-L1 levels and these inflammatory biomarkers in patients with esophageal cancer have not been documented so far.

Therefore, in this present study, we evaluated the clinicopathological and prognostic significance of serum PD-L1 levels in surgically treated esophageal cancer patients. Additionally, we evaluated the relationship among laboratory parameters, inflammatory markers, and serum PD-L1 levels.

2 MATERIALS AND METHODS

2.1 Study groups

A total of 150 patients with esophageal cancer who underwent radical surgery at the Toho University Hospital between January 2010 and October 2017 were included in this study. Among them, 87 patients received neoadjuvant chemotherapy. The number of patients in each stage according to the Japanese Classification of Esophageal Cancer (11th Edition) is as follows: stage 0, 11; stage I, 26; stage II, 41; stage III, 57; and stage IVa, 15. All patients were regularly followed up until July 2018 or death. None of the patients had received anti-PD-1 or anti-PD-L1 antibody treatment. Written informed consent was obtained from all the patients, and the study was approved by the Ethics Committee of the Toho University School of Medicine (nos. A18103).

2.2 Serum sampling and enzyme immunoassay for serum markers

Serum samples were collected prior to treatment and stored at −80°C until the assays were performed. Expression levels of serum p-53 antibodies (p53-Abs) and squamous cell carcinoma antigen (SCC-Ag) were evaluated. The cutoff values for serum p53-Abs and SCC-Ag were fixed at 1.3 IU/ml and 1.5 ng/ml, respectively. Serum PD-L1 levels were measured using a commercially available enzyme-linked immunosorbent assay kit for PD-L1 (R&D Systems, Minneapolis, MN, USA). This assay employs the quantitative sandwich enzyme immunoassay technique using a monoclonal antibody specific for human B7-H1 pre-coated onto a microplate. We determined the serum PD-L1 levels in the collected samples according to the manufacturer’s protocol. We evaluated the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with serum PD-L1 level. The cut off level of NLR and PLR was set as follows NLR; 1.6, PLR; 117.07 according to previous reports.

2.3 Statistical analysis

Continuous data are expressed as mean ± standard deviation. Comparisons between continuous data were carried out using the Mann-Whitney U test. Differences in the distribution of two variables were evaluated using Fisher's exact test or χ2 test and the corresponding differences among three variables using Kruskal-Wallis test. The association between clinicopathological data and serum PD-L1 levels was analyzed using logistic regression analysis. Survival curves were calculated using the Kaplan-Meier method and

FIGURE 1 Comparison of serum PD-L1 levels according to each stage by Japanese Classification of Esophageal Cancer. Statistical analysis was performed by the Kruskal-Wallis test.
compared using the log-rank test. Significant predictors were assessed by multivariate analysis using the Cox proportional hazards model. All analyses were performed using the EZR software. Statistical significance levels were defined as $P < .05$.

3 RESULTS

3.1 Serum PD-L1 level according to the TNM stage

The mean levels of serum PD-L1 at each stage were as follows: 37.4 ± 12.2 pg/ml (stage 0), 45.0 ± 30.3 pg/ml (stage I), 55.6 ± 29.0 pg/ml (stage II), 54.5 ± 38.4 pg/ml (stage III), and 53.3 ± 37.5 pg/ml (stage IV). No significant differences in serum PD-L1 levels were observed among the five stages (Figure 1).

### 3.2 Comparison of serum PD-L1 levels according to various laboratory data

As seen in Table 1, serum PD-L1 levels were significantly correlated with neutrophil counts and CRP, albumin, and SCC-Ag levels; in addition, correlations were observed among serum PD-L1 level, advanced-stage cancer, and lymphocyte counts (statistical significance notwithstanding). Alternatively, the serum PD-L1 levels were not correlated with tumor depth, lymph node status, WBC and platelet counts, and serum p53 antibody and hemoglobin levels.

### 3.3 Relationship between serum PD-L1 levels and overall survival

In order to clarify the cutoff level of serum PD-L1, we divided into every one-fourth into four groups, Q 1, Q 2, Q 3,

| TABLE 1 | Comparison of serum PD-L1 levels according to various laboratory data of the patients with esophageal carcinoma |
|----------|-------------------------------------------------------------------------------------------------|
| Number of patients | Median (min-max) | $P$ value$^a$ |
| **Tumor depth** | | |
| Tis, T1 | 53 | 43.1 (1.18-119.2) | .12 |
| T2 T3 T4 | 97 | 51.5 (2.40-235.1) | |
| **Lymph node status** | | |
| Negative | 61 | 47.0 (1.18-119.9) | .60 |
| Positive | 89 | 51.1 (2.40-235.1) | |
| **Stage** | | |
| 0 I | 37 | 37.0 (1.18-119.2) | .08 |
| II III IV | 113 | 52.0 (2.40-235.1) | |
| **WBC(/μl)** | | |
| >8000 | 136 | 45.2 (7.35-96.6) | .55 |
| $\leq$8000 | 14 | 50.2 (1.18-235.1) | |
| **Neutrophil (%)** | | |
| $>70$ | 37 | 59.1 (11.1-151.7) | <.01 |
| $\leq70$ | 113 | 44.6 (0.0-235.1) | |
| **Lymphocyte (%)** | | |
| $>35$ | 35 | 43.4 (6.59-105.0) | .06 |
| $\leq35$ | 115 | 52.3 (0.0-235.1) | |
| **Hemoglobin (g/dl)$^b$** | | |
| $>12$ | 75 | 44.1 (1.18-119.2) | .10 |
| $\leq12$ | 74 | 52.0 (6.59-235.1) | |
| **Platelet** | | |
| $>150,000$ | 128 | 49.4 (1.18-235.1) | .80 |
| $\leq150,000$ | 12 | 53.2 (11.4-151.7) | |
| **CRP(mg/dl)$^b$** | | |
| $>0.3$ | 64 | 55.7 (1.18-235.1) | .02 |
| $\leq0.3$ | 81 | 46.2 (2.40-119.9) | |
| **Albumin (g/dl)** | | |
| $>3.5$ | 119 | 46.3 (1.18-151.7) | <.01 |
| $\leq3.5$ | 31 | 63.1 (14.1-235.1) | |
| **SCC-Ag(ng/ml)$^b$** | | |
| Negative | 92 | 44.6 (1.18-235.1) | <.01 |
| Positive | 55 | 58.3 (6.59-165.8) | |
| **p53-Abs(U/ml)$^b$** | | |
| Negative | 108 | 47.3 (1.18-235.1) | .29 |
| Positive | 35 | 52.0 (11.1-125.1) | |

Bold values indicate significant differences.

$^a$Mann-Whitney $U$ Test.

$^b$Loss value.
and Q 4 (Figure 2A). The serum PD-L1 level of Q1 ranged from 0.0 to 28.3 pg/ml, Q2 ranged from 29.0 to 48.3 pg/ml, Q3 ranged from 49.0 to 65.6 pg/ml and Q4 ranged from 66.1 to 235 pg/ml, and no significant differences in survival were noted among groups Q1, Q2, and Q3. However, Q4 showed significantly worse survival than the other groups (Figure 2B, \( P < .01 \)). Therefore, the cutoff value of serum PD-L1 was fixed at 65.6 pg/ml in order to compare the clinicopathological factors among Q1, Q2, Q3, and Q4.

### 3.4 Relationship between high serum PD-L1 level and clinicopathological factors

Serum PD-L1 levels were significantly associated with SCC-Ag in the univariate and multivariate analyses (Table 2), but not with gender, age, location, tumor depth, lymph node metastasis, p53 antibody level. There was no statistically significant correlation between NLR or PLR with serum PD-L1 in the univariate and multivariate analyses.

| Variables                     | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | PD-L1 ≤ 65.6 pg/ml (Q1 + Q2 + Q3) | PD-L1 > 65.6 pg/ml (Q4) | \( P \) value\(^a\) | odds ratio | 95% CI | \( P \) value\(^b\) |
| Gender                       | Male                | 90                    | 32                    | .64        |
|                              | Female              | 22                    | 6                     |
| Age                          | >65                 | 58                    | 24                    | .26        |
|                              | ≤65                 | 54                    | 14                    |
| Location\(^c\)               | Upper               | 16                    | 5                     | 1.00       |
|                              | Lower               | 92                    | 30                    |
| Tumor depth\(^c\)            | T1                  | 42                    | 8                     | .15        | 0.88    | 0.30-2.59 | .82 |
|                              | T2-T4               | 66                    | 26                    |
| Lymph node metastasis\(^c\)  | N0                  | 48                    | 11                    | .25        | 1.50    | 0.59-3.82 | .40 |
|                              | N1                  | 61                    | 24                    |
| SCC (ng/ml)\(^c\)            | >1.5                | 31                    | 21                    | \(<.01\)    | 3.93    | 1.57-9.83 | \(<.01\) |
|                              | ≤1.5                | 75                    | 12                    |
| p53-Abs (U/ml)\(^c\)         | >1.30               | 24                    | 9                     | .65        |
|                              | ≤1.30               | 79                    | 24                    |
| NLR\(^c\)                    | ≥1.6                | 74                    | 28                    | .19        |
|                              | <1.6                | 33                    | 6                     |
| PLR\(^c\)                    | ≥117.07             | 72                    | 28                    | .13        | 1.83    | 0.66-5.05 | .24 |
|                              | ≤117.07             | 35                    | 6                     |

Bold values indicate significant differences.

\(^a\)Fisher’s exact probability test.

\(^b\)Logistic regression analysis.

\(^c\)Loss value.
Table 3: Univariate and multivariate analysis of risk factors for overall survival in the 150 patients with esophageal carcinoma

| Risk Factor                  | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
|                              | P value             | Hazard ratio          |
|                              |                     | 95% CI                 |
| Gender                       | .08                 |                       |
| Male/ Female                 |                     |                       |
| Age                          | .36                 |                       |
| >65/ ≤65                     |                     |                       |
| Location                     | .60                 |                       |
| Upper/Lower                  |                     |                       |
| Tumor depth                  | <.01                | 2.76                  |
| T1/T2-4                      |                     | 1.49-5.11             |
| Lymph node metastasis        | <.01                | 2.30                  |
| N-/N+                        |                     | 1.32-4.01             |
| SCC-Ag(ng/ml)                | .02                 |                       |
| >1.5/ ≤1.5                   |                     |                       |
| p53-Abs(U/ml)                | .19                 |                       |
| >1.30/ ≤1.30                 |                     |                       |
| PD-L1 (pg/ml)                | <.01                | 1.70                  |
| Q4/ Q1 + Q2 + Q3             |                     | 1.03-2.80             |
| NLR                          | .63                 |                       |
| ≥1.6/ <1.6                   |                     |                       |
| PLR                          | .44                 |                       |
| ≥117.07/ <117.07             |                     |                       |

Bold values indicate significant differences.

*Log-rank test
*Adjusted 95% confidence interval
*Cox proportional hazard model

3.5 Univariate and multivariate analyses of risk factors on survival

In the univariate analysis, patients with high serum PD-L1 levels showed significantly worse overall survival than those with low serum PD-L1 levels (Table 3, left panel). Tumor depth, lymph node metastasis, high SCC-Ag level were also significant prognostic factors. In the multivariate analysis, a high serum PD-L1 level was significantly associated with poor survival (Table 3, P = .04). However, NLR and PLR were not shown significantly worse overall survival.

4 Discussion

Serum PD-L1 levels were positively correlated with neutrophil counts and CRP and SCC-Ag levels and negatively correlated with albumin levels in patients with surgically treated esophageal cancer in this study. Although serum PD-L1 level was not associated with tumor stage, it was an independent risk factor for poor overall survival.

Based on the results of the multivariate analysis, high serum PD-L1 level was noted as an independent prognostic predictor. One of the explanations for the malignant potential of high serum PD-L1 levels was that they were the surrogate markers for PD-L1-positive tumor cells, which are known to demonstrate high malignant potentials. PD-L1 is mainly expressed in tumor cells; therefore, high concentrations of PD-L1 represent large tumor volumes and/or highly malignant tumors. On the other hand, several reports have demonstrated no significant associations between tumoral PD-L1 expression and serum PD-L1 levels, suggestive of the fact that a high level of serum PD-L1 might be related to the immunological condition of the patient. Similar to hepatocellular carcinoma and gastric cancer, no associations were noted between serum PD-L1 levels and tumor stage or tumor size. Increased levels of inflammatory cytokines in the serum might contribute to an increase in the levels of serum PD-L1, but not tissue PD-L1 expression.
There was no statistically significant correlation in NLR and PLR with high serum PD-L1 level in Fisher’s exact probability test (Table 2). In multivariate analysis, there was not seen positive correlation with PLR in Logistic regression analysis. And NLR did not show tendency to significant even in univariate analysis. When both NLR and PLR were included in the multivariate analysis, there was a possibility of becoming these scores as compound factor with each other in the Logistic regression analysis. Therefore, we decided to put only PLR and excluded NLR.

One of the limitations of this study was that no immunohistochemical analysis was performed to evaluate the impact of tissue protein expression on serum PD-L1 levels. Serum PD-L1 may be produced by multiple sources via distinct mechanisms from both tumor and immune cells. Several reports have shown that serum PD-L1 levels might be influenced by inflammatory cytokine induction. Likewise, the present study also demonstrated interactions between serum PD-L1 levels and several inflammatory biomarkers. Secondly, the relationship between serum PD-L1 levels before and after treatment was not compared in this study. Changes in serum PD-L1 levels may be an indicator of recurrence or prognosis. However, studies have reported an increase in serum PD-L1 levels after radiotherapy in hepatocellular carcinoma and chemoradiotherapy in rectal cancer. Perioperative or peritreatment changes in serum PD-L1 levels in patients with esophageal cancer may have a clinical significance in predicting the treatment response and/or the prognosis. The relationship between serum PD-L1 level and treatment response to immune checkpoint inhibitors should be evaluated in the future.

5 | CONCLUSION

Serum PD-L1 levels were positively correlated with high levels of inflammatory markers and/or SCC-Ag levels. Despite the lack of any association with tumor stage, serum PD-L1 level was found to be an independent risk factor for overall poor survival in surgically treated esophageal cancer.

ACKNOWLEDGMENTS
We thank Ms Seiko Otsuka for preparing patient data.

CONFLICT OF INTEREST
The authors have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Hideaki Shimada https://orcid.org/0000-0002-1990-8217

REFERENCES
1. Shimada H. p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2018;2:266-273.
2. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 1. Esophagus. 2019;16:1-24.
3. Shtiera K, Özgüroğlu M, Bang Y-J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123-133.
4. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631-639.
5. Ito M, Oshima Y, Yajima S, et al. Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer? Ann Gastroenterol Surg. 2018;2:313-318.
6. Shigemori T, Toiyama Y, Okugawa Y, et al. Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Ann Surg Oncol. 2019;26:876-883.
7. Takahashi N, Iwasa S, Sasaki Y, et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol. 2016;142:1727-1738.
8. Finkelmeier F, Canli O, Tal A, et al. High levels of the soluble programmed death-ligand (sPD-L1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7:76604-76612.
9. Akutsu Y, Murakami K, Kano M, et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus. 2018;15:103-108.
10. Weber M, Wehrhan F, Baran C, et al. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma—a comparison to the PD-L1 expression profile. Cancer Med. 2019;8:1124-1134.
11. Ha H, Nam A-R, Bang J-H, et al. Soluble programmed death-ligand 1 (sPD-L1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7:7913-7924.
12. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus 2017;14:1-36.
13. Shimada H, Ochiai T, Nomura F. Japan p53 antibody research group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multinational analysis by the Japan p53 antibody research group. Cancer. 2003;97:682-689.
14. Shimada H, Nabeya Y, Okazumi S-I, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486-494.
15. Mizuguchi S, Izumi N, Tsukioka T, Komatsu H, Nishiyama N. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer. J Cardiothorac Surg. 2018;13:78.
17. Geng Y, Shao Y, Zhu D, et al. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. *Sci Rep*. 2016;6:39482.

18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant*. 2013;48:452-458.

19. Rong L, Liu Y, Hui Z, et al. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. *Diagn Pathol*. 2019;14:6.

20. Jiang Y, Lo AWI, Wong A, et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. *Oncotarget*. 2017;8:30175-30189.

21. Yoshida J, Ishikawa T, Doi T, et al. Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer. *Med Oncol*. 2019;36:60.

22. Kruger S, Legenstein M-L, Rösgen V, et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. *Oncoimmunology*. 2017;6:e1310358.

23. Aghajani M, Roberts T, Yang T, et al. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. *Endocr Connect*. 2019;8(7):1040–1051. pii: EC-19-0210.R1.

24. Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-L1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. *Cancer Immunol Immunother*. 2019;68:353-363.

25. Zhou J, Mahoney KM, Giobbie-Hurder A, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. *Cancer Immunol Res*. 2017;5:480-492.

26. Akamine T, Takada K, Toyokawa G, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: a comprehensive analysis of systemic inflammatory markers. *Surg Oncol*. 2018;27:88-94.

27. Park H, Bang J-H, Nam A-R, et al. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. *Sci Rep*. 2019;9:11131.

28. Kim HJ, Park S, Kim KJ, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. *Radiother Oncol*. 2018;129:130-135.

29. Tominaga T, Akiyoshi T, Yamamoto N, et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand-1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. *PLoS ONE*. 2019;14:e0212978.

How to cite this article: Ito M, Yajima S, Suzuki T, et al. High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer. *Cancer Med*. 2020;9:1321–1327. [https://doi.org/10.1002/cam4.2789](https://doi.org/10.1002/cam4.2789)